Sitagliptin/Metformin Medical Valley 50 mg / 1000 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin/metformin medical valley 50 mg / 1000 mg

medical valley invest ab - sitagliptinhydroklorid / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Sitagliptin Glenmark 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin glenmark 50 mg

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 50 mg

Sitagliptin Glenmark 25 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin glenmark 25 mg

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 25 mg

Sitagliptin Glenmark 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin glenmark 100 mg

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 100 mg

Sitagliptin SUN ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sitagliptin Hexal 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin hexal 50 mg

hexal a/s - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 50 mg

Sitagliptin Hexal 25 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin hexal 25 mg

hexal a/s - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 25 mg

Sitagliptin Hexal 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin hexal 100 mg

hexal a/s - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 100 mg

Sitagliptin Sandoz 25 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin sandoz 25 mg

sandoz - københavn - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 25 mg

Sitagliptin Sandoz 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sitagliptin sandoz 50 mg

sandoz - københavn - sitagliptinhydrokloridmonohydrat - tablett, filmdrasjert - 50 mg